Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Kala Pharmaceuticals, Inc is a biotechnology business based in the US. Kala Pharmaceuticals shares (KALA) are listed on the NASDAQ and all prices are listed in US Dollars. Kala Pharmaceuticals employs 188 staff and has a trailing 12-month revenue of around USD$6.4 million.
|52-week range||USD$5.04 - USD$14.68|
|50-day moving average||USD$8.2438|
|200-day moving average||USD$7.9365|
|Wall St. target price||USD$21.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.866|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$6.4 million|
|Gross profit TTM||USD$4.2 million|
|Return on assets TTM||-31.67%|
|Return on equity TTM||-160.89%|
|Market capitalisation||USD$453 million|
TTM: trailing 12 months
There are currently 9.3 million Kala Pharmaceuticals shares held short by investors – that's known as Kala Pharmaceuticals's "short interest". This figure is 1.4% down from 9.5 million last month.
There are a few different ways that this level of interest in shorting Kala Pharmaceuticals shares can be evaluated.
Kala Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Kala Pharmaceuticals shares currently shorted divided by the average quantity of Kala Pharmaceuticals shares traded daily (recently around 2.2 million). Kala Pharmaceuticals's SIR currently stands at 4.22. In other words for every 100,000 Kala Pharmaceuticals shares traded daily on the market, roughly 4220 shares are currently held short.
However Kala Pharmaceuticals's short interest can also be evaluated against the total number of Kala Pharmaceuticals shares, or, against the total number of tradable Kala Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kala Pharmaceuticals's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Kala Pharmaceuticals shares in existence, roughly 170 shares are currently held short) or 0.236% of the tradable shares (for every 100,000 tradable Kala Pharmaceuticals shares, roughly 236 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kala Pharmaceuticals.
Find out more about how you can short Kala Pharmaceuticals stock.
We're not expecting Kala Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Kala Pharmaceuticals's shares have ranged in value from as little as $5.04 up to $14.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kala Pharmaceuticals's is 0.3955. This would suggest that Kala Pharmaceuticals's shares are less volatile than average (for this exchange).
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.